Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial

Ripretinib, an oral investigational tyrosine kinase inhibitor, significantly improved median progression-free survival vs placebo with an acceptable safety profile in 129 patients with treatment resistant disease (6.3 vs 1.0 months; HR 0.15, 95% CI 0.09–0.25; p<0.0001).


The Lancet Oncology